
Julie Grisham
Science and Medical Writer at Freelance
I don't know what to say... Ha! I always know what to say.
Articles
-
1 week ago |
mskcc.org | Julie Grisham
As Jan Gura prepared to face the onslaught of standard treatments for stage 2 ovarian cancer, she knew she also wanted integrative therapies that would help her feel better. “I didn’t know how my body would respond to chemotherapy, but I’ve always been an active person. Being able to maintain that was important to me,” she says.
-
2 weeks ago |
mskcc.org | Julie Grisham
Researchers at Memorial Sloan Kettering Cancer Center (MSK), the University of California, San Francisco (UCSF), and University of California, Berkeley (UC Berkeley) have developed an artificial intelligence (AI) tool called DeepHeme that can help automate the diagnosis of blood and bone marrow cancers. The study was published on June 11 in Science Translational Medicine.
-
1 month ago |
mskcc.org | Julie Grisham
Researchers from Memorial Sloan Kettering Cancer Center (MSK) reported important advances in the treatment of lung cancer at the annual meeting of the American Society of Clinical Oncology (ASCO), held May 30 to June 3 in Chicago. Scientists presented promising results on three different targeted therapies — one for small cell lung cancer and two for non-small cell lung cancer.
-
1 month ago |
mskcc.org | Julie Grisham
Memorial Sloan Kettering Cancer Center (MSK) celebrated new graduates and award winners at the Academic Convocation and Commencement, held on May 14. In 2025, 14 students earned their doctoral degrees in cancer biology from the Gerstner Sloan Kettering Graduate School of Biomedical Sciences (GSK) — the educational division of MSK. In addition, two practicing MSK doctors received Master of Science degrees in clinical and translational cancer research from GSK.
-
1 month ago |
mskcc.org | Julie Grisham
The first drug for a rare and difficult-to-treat type of ovarian cancer has been granted accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus defactinib (Avmapki Fakzynja Co-pack), was developed to treat low-grade serous ovarian cancer (LGSOC). The phase 2 clinical trial that resulted in the approval was led in the United States by gynecologic medical oncologist Rachel Grisham, MD, of Memorial Sloan Kettering Cancer Center (MSK).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 42
- Tweets
- 0
- DMs Open
- No